Insight: A $165 Million Fund, and the Question It Can't Answer Alone

Coefficient Giving's new Health Aid Transition Fund is built on the same bet BAROS-AFRICA has made from day one — that technical assistance has to prove itself, not just claim to work.

Source note: this piece draws on Coefficient Giving's September 18, 2026 announcement of the Health Aid Transition Fund, and also references the International AIDS Society's September 2026 Request for Proposals. Quotations are kept short and attributed.

Global health aid dropped more than 20% between 2024 and 2025, and the bilateral agreements replacing U.S. contributions now ask governments to co-finance roughly 40% of health funding on average — a steep jump for programs that have historically run with no government cost-share at all. Sub-Saharan Africa drew roughly 6.4% of GDP from this kind of aid before the cuts started. This isn't a gradual shift. It's a small number of budget cycles deciding what these health systems look like for years afterward.

Coefficient Giving's answer is a $165 million Health Aid Transition Fund, built on nearly $18 million in grants already made. The model is technical assistance, specifically: cost analyses, financing strategy, help moving allocated money out the door, and bridge financing to keep programs running through the handover itself.

The Same Bet, Arrived At Independently

The Fund's own stated concerns read like a direct description of the problem BAROS-AFRICA's fiscal architecture work already targets. Ministries of health signing an MOU doesn't guarantee the ministry of finance shares the same goal — the two have to move the financing forward together, and often don't start aligned. And separately, governments frequently spend well under what they've actually allocated, not because the money isn't budgeted but because treasury releases cash late, or payments to health providers and commodity suppliers move slowly once it's released. Neither of these is a financing gap in the way aid cuts are a financing gap. They're execution gaps — the money exists, but the plumbing between the budget line and the clinic doesn't move it reliably. That's a fiscal architecture problem, not a fundraising one, and it's exactly the layer BAROS-AFRICA's own G2G Fiscal Architecture work sits in.

The Honest Gap It Names Itself

What's more interesting than the alignment is the caveat the Fund's own leadership volunteers without being asked: technical assistance, as a category, has a mixed track record. That's not a rhetorical hedge — it's the correct, honest answer, and it's the same problem the BAROS Sustainability Index exists to solve. A transition can look complete — government logo on the letterhead, government staff in the org chart — while the system underneath is still quietly dependent on outside help to actually function. The Fund is betting real money that its technical assistance will be the kind that holds. The only way to know, rather than hope, is to measure the gap between looking transitioned and being transitioned directly, which is a different exercise than measuring whether the technical assistance was delivered on schedule.

What This Actually Points To

The Fund also flags something easy to miss: where an existing network of private clinics or pharmacies can deliver a service like malaria testing and treatment more cheaply than a facility built and staffed from scratch, funding through that existing private network can be the more efficient path — not a compromise on public financing, just a more honest accounting of what building a parallel system actually costs. That's a genuinely different design question than most transition planning asks, and one with a real, private-sector-shaped answer rather than a purely public-sector one.

That thinking already has a concrete example attached to it. The International AIDS Society opened a request for proposals this month funding organizations to map the practical pathway to pharmacy-delivered PrEP and PEP in specific countries — building on pilot studies that already found the approach feasible and acceptable in Kenya and South Africa, two of the countries where a pharmacy counter, not a clinic, may end up being the actual point of delivery. It's a small grant against a $165 million fund, but it's the same underlying bet: that the fastest, most durable path to a service reaching people isn't always building or preserving a parallel system, even a well-intentioned one.

None of this makes the transition easy. The Fund's own list of risks — cross-ministry buy-in, execution efficiency, the plain politics of reallocating a budget away from an existing hospital toward a needier rural clinic — is a realistic one, not a marketing list. But a philanthropic funder putting $165 million behind the premise that aid-financed health systems should become government-financed ones, and saying so plainly, is a real and useful thing to have on the record this month, regardless of how any one grant relationship does or doesn't unfold from here.